See also: Generic Lescol
Lescol XL is a brand name of fluvastatin, approved by the FDA in the following formulation(s):
LESCOL XL (fluvastatin sodium - tablet, extended release; oral)
Manufacturer: NOVARTIS
Approval date: October 6, 2000
Strength(s): 80MG [RLD]
Has a generic version of Lescol XL been approved?
No. There is currently no therapeutically equivalent version of Lescol XL available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lescol XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Indole analogs of mevalonolactone and derivatives thereof
Patent 5,354,772
Issued: October 11, 1994
Inventor(s): Kathawala; Faizulla G.
Assignee(s): Sandoz Pharm. Corp.
Compounds of the formula ##STR1## wherein one of R and R.sub.o is ##STR2## and the other is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --, wherein R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy, R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy, X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3, and Z is ##STR3## wherein R.sub.6 is hydrogen or C.sub.1-3 alkyl, and R.sub.7 is hydrogen, R.sub.7b or M, wherein R.sub.7b is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and therefore, in the treatment of hyperliopoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.
Patent expiration dates:
- October 11, 2011
✓
Patent use: USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
- October 11, 2011
✓
Patent use: ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
- April 11, 2012
✓
Pediatric exclusivity
Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound
Patent 5,356,896
Issued: October 18, 1994
Inventor(s): Kabadi; Mohan B. & Vivilecchia; Richard V.
Assignee(s): Sandoz Ltd.
A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g., fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition.
Patent expiration dates:
- December 12, 2011
- June 12, 2012
✓
Pediatric exclusivity
Organic compounds
Patent 6,242,003
Issued: June 5, 2001
Inventor(s): Kalb; Oskar Michael & Valazza; Stephen John
Assignee(s): Novartis AG
An oral dosage form comprising fluvastatin and HPMC, which oral dosage form is color-stable upon prolonged periods of storage.
Patent expiration dates:
- April 13, 2020
- October 13, 2020
✓
Pediatric exclusivity
See also...
- Lescol XL Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Lescol XL Consumer Information (Cerner Multum)
- Lescol XL Advanced Consumer Information (Micromedex)
- Fluvastatin Consumer Information (Wolters Kluwer)
- Fluvastatin Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Fluvastatin Consumer Information (Cerner Multum)
- Fluvastatin Advanced Consumer Information (Micromedex)
- Fluvastatin Sodium AHFS DI Monographs (ASHP)
